altretamine
Trade name: hexalen
Small moleculeapprovedOrphan Drug FDA
Approved
Dec 26, 1990
TRIETHYLENEMELAMINE, an aziridine derivative, is an alkylating agent with antineoplastic properties. Formerly it was used in the palliative treatment of the lymphomas and leukemias. Now it is used as a research tool to produce chromosome aberrations and cancers. — NCATS
Clinical trial activity
4 trials · 4 clinical orgs · 2 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 1996 (NCT00002936)
Timeline
1980s
- Feb 9, 1984
Orphan Drug Designation
1990s
- Dec 26, 1990
US Bioscience — Earliest FDA Approval
- Dec 26, 1990
US Bioscience — NDA Organization
- Dec 26, 1990
Eisai — NDA Secondary Org
- Jan 1, 1996
Earliest Phase 1 Sponsor(trial)
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Approval history
- approvedPriority reviewDec 26, 1990
Chemistry & pharmacology
Loading structure…
SMILES
C1CN1C2=NC(=NC(=N2)N3CC3)N4CC4- Mol. weight
- 204.2318 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Black box warning
Sources
- WikipediaAltretamine ↗
- NCATSF7IY6HZG9D ↗
- ChEMBLCHEMBL502384 ↗
- ChEMBLCHEMBL3137348 ↗
- ChEMBLCHEMBL1455 ↗
- NCATSQ8BIH59O7H ↗
Also known as
- 2,4,6-tris(dimethylamino)-1,3,5-triazine
- 2,4,6-tris(dimethylamino)-1,3,5-triazine
- 2,4,6-tris(dimethylamino)-s-triazine
- 2,4,6-tris(dimethylamino)-s-triazine
- agn-214868
- agn-214868
- altretamin
- altretamin
- altretamina
- altretamina
- altretamine
- altretamine
- altretamine
- altretamine
- altretamine
- altretamine
- altretamine
- altretamine
- altretamine
- altretamine
- altretamine
- altrétamine
- altrétamine
- altretaminum
- altretaminum
- hexalen
- hexalen
- hexalen
- hexalen
- hexamethylmelamine
- hexamethylmelamine
- hexamethylmelamine
- hexamethylmelamine
- hexastat
- hexastat
- hexastat
- hexylen
- hmm
- hmm
- senrebotase
- senrebotase
- senrebotase
- sxn-100323
- tretamin
- tretamine
- tretamine
- triamelin
- triaziridinyl triazine
- triethanomelamine
- triethylenemelamine
- triethylenemelamine
- triethylenemelamine
- triethylenemelamine
- triethylenemelamine
- trisaziridinyltriazine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01678924 | Phase 2 | Jan 1, 2013 | Allergan |
| NCT01157377 | Phase 2 | Oct 1, 2010 | Allergan |
| NCT01129531 | Phase 2 | Jun 1, 2010 | Allergan |
| NCT00002936 | Phase 1 | Jul 1, 1996 | Albany Medical College, National Cancer Institute (NCI), State University of New York, Buffalo |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 3 | 3 | 1 | 2010 |
| Albany Medical College | Academic/Hospital | 1 | 0 | 1 | 1996 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1996 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 1996 |
4 organizations
Page 1 / 1
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Eisai | For profit | NDA2 | Dec 26, 1990 |
| US Bioscience | For profit | NDA | Dec 26, 1990 |